SEARCH

SEARCH BY CITATION

References

  • 1
    Kinkhabwala M, Rudow DL, Harren P et al. Model for end-stage liver disease and Child-Turcotte-Pugh score as predictors of pretransplantation disease severity, posttransplantation outcome, and resource utilization in United Network for Organ Sharing status 2A patients. Liver Transpl 2002; 8: 278284.
  • 2
    Sheth M, Riggs M, Patel T. Utility of the Mayo End-Stage Liver Disease (MELD) score in assessing prognosis of patients with alcoholic hepatitis. BMC Gastroenterol 2002; 2: 2.
  • 3
    Pagliaro L. MELD: the end of Child-Pugh classification? J Hepatol 2002; 36: 141142.
  • 4
    Edwards EB, Malinchoc M, Kremers WK et al. MELD and PELD: application of survival models to liver allocation. Liver Transpl 2001; 7: 567580.
  • 5
    McCaughan GW, Strasser SI. To MELD or not to MELD? Hepatology 2001; 34: 215216.
  • 6
    Kremers W, Therneau TM, Kosberg CL et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464470.
  • 7
    Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, Ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000; 31: 864871.
  • 8
    Kamath PS, Kremers WK, Weinstein JS et al. Prediction of liver transplantation outcome based on pretransplant disease severity: is there anything better than MELD? [abstract] Hepatology 2001; 34 (4 Part 2): 235A.
  • 9
    Desmet VJ, Gerber M, Hoofnagle JH, Manna M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19: 15131520.
  • 10
    Irish W, McMichael J, Demetris AJ et al. Clinical outcome of patients infected with hepatitis C virus infection on survival after primary liver transplantation under tacrolimus. Liver Transpl Surg 1998; 4: 448454.
  • 11
    Colquhoun S, Rosen HR, Yersiz H et al. Orthotopic liver transplantation for hepatitis C. outcome, effect of immunosuppression, and causes of retransplantation during an 8-year single-center experience. Ann Surg 1999; 229: 824831.
  • 12
    Goldstein RM, Jennings LW, Brkic BS et al. Liver transplantation for hepatitis C: recurrence and disease progression in 300 patients. Liver Transpl 2000; 6: 553561.
  • 13
    Prieto M, Kim M, Rayon M et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000; 32: 673684.
  • 14
    Bizollon T, Trepo C. Transplantation in HCV: whither immunosuppression. Gut 1999; 45: 327328.
  • 15
    Bizollon T, Ducerf C, Trepo C, Mutimer D. Hepatitis C virus recurrence after liver transplantation. Gut 1999; 44: 575578.
  • 16
    Rosen HR, Martin P. Hepatitis C infection in patients undergoing liver retransplantation. Transplantation 1998; 66: 16121616.
  • 17
    Forman LM, Lucey MR. Predicting the prognosis of chronic liver disease: an evolution from child to MELD: Mayo End-Stage Liver Disease. Hepatology 2001; 33: 473475.
  • 18
    Mora J, Pastor M, Ortiz V et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000; 32 (4 Part 1): 852858.
  • 19
    Smith HM, Underhill JA, Donaldson PT et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996; 334: 815820.
  • 20
    Flora KD, Benner KG, Rabkin JM et al. Timing and severity of initial hepatitis C recurrence as predictors of long-term liver allograft injury. Transplantation 1998; 65: 11781182.